Your browser doesn't support javascript.
loading
Human leukocyte antigen Class II alleles associated with acral lentiginous melanoma in Mexican Mestizo patients: A case-control study.
Roldan-Marin, Rodrigo; Rangel-Gamboa, Lucia; Vega-Memije, María E; Hernández-Doño, Susana; Ruiz-Gómez, Daniela; Granados, Julio.
  • Roldan-Marin R; OncoDermatology Clinic, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico.
  • Rangel-Gamboa L; Ecology of Pathogenic Agents, Division of Research, General Hospital Dr. Manuel Gea González, Mexico.
  • Vega-Memije ME; Department of Dermatology, General Hospital Dr. Manuel Gea González, Mexico.
  • Hernández-Doño S; Department of Transplant, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Ruiz-Gómez D; Department of Internal Medicine, Fundación Clínica Médica Sur A.C, Mexico.
  • Granados J; Department of Transplant, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Indian J Dermatol Venereol Leprol ; 88(5): 608-614, 2022.
Article en En | MEDLINE | ID: mdl-35138055
ABSTRACT
Background Melanoma is an aggressive cutaneous cancer. Acral lentiginous melanoma is a melanoma subtype arising on palms, soles, and nail-units. The incidence, prevalence and prognosis differ among populations. The link between expression of major histocompatibility complex Class II alleles and melanoma progression is known. However, available studies report variable results regarding the association of melanoma with specific HLA Class II loci. Aims The aim of the study was to determine HLA Class II allele frequencies in acral lentiginous melanoma patients and healthy Mexican Mestizo individuals. Methods Eighteen patients with acral lentiginous melanoma and 99 healthy controls were recruited. HLA Class II typing was performed based on the sequence-specific oligonucleotide method. Results Three alleles were associated with increased susceptibility to develop acral lentiginous melanoma, namely HLA-DRB1*1301; pC = 0.02, odds ratio = 6.1, IC95% = 1.4-25.5, HLA-DQA1*0103; pC = 0.001, odds ratio = 9.3, IC95% = 2.7-31.3 and HLA-DQB1*0202; pC = 0.01, odds ratio = 3.7, IC95% = 1.4-10.3. Limitations The small sample size was a major limitation, although it included all acral lentiginous melanoma patients seen at the dermatology department of Dr. Manuel Gea González General Hospital during the study period. Conclusion HLA-DRB1*1301, HLA-DQB1*0202 and HLA-DQA*0103 alleles are associated with increased susceptibility to develop acral lentiginous melanoma in Mexican Mestizo patients.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Melanoma Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans País como asunto: Mexico Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Melanoma Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans País como asunto: Mexico Idioma: En Año: 2022 Tipo del documento: Article